‘Game changer’ semaglutide halves diabetes risk from obesitySeptember 19, 2022ObesityDiabetesCardiology
Atezolizumab doubles survival of NSCLC patients with poor performance statusSeptember 19, 2022Lung CancerOncology
Brodalumab suicide risk similar to other biologics, postmarket study findsSeptember 19, 2022DermatologyMental HealthMixed Topics
A farewell to arms? Drug approvals based on single-arm trials can be flawedSeptember 19, 2022OncologyMixed TopicsBreast CancerGenitourinary CancerLung CancerMelanomaRare Diseases
Sustained response at 2 years reported for newly approved oral psoriasis agentSeptember 15, 2022Dermatology
Pembro/chemo combo fails to improve event-free survival in head and neck cancerSeptember 14, 2022Oncology
Clozapine may be best choice for cutting SUD risk in schizophreniaSeptember 13, 2022Addiction MedicineMental Health
Psychiatrists’ views on psychoactive drugs clash with U.S. policySeptember 8, 2022Addiction MedicineBusiness of MedicineMental HealthDepression
DOJ: Indiana nurses allowed controlled substances during opioid recoverySeptember 6, 2022Addiction Medicine
